Cancer characteristics and treatments initiated at inclusion
| . | N = 3032, no. (%) . |
|---|---|
| Site of the primary cancer | |
| Breast | 1023 (33.7) |
| Lung | 560 (18.5) |
| Colorectal | 472 (15.6) |
| Upper aerodigestive tract | 168 (5.5) |
| Pancreas | 162 (5.3) |
| Prostate | 108 (3.6) |
| Gastric | 103 (3.4) |
| Ovarian or peritoneal | 98 (3.2) |
| Bladder or urinary tract | 92 (3.0) |
| Liver or biliary tract | 65 (2.1) |
| Uterus | 64 (2.1) |
| Testis | 25 (0.8) |
| Kidney | 24 (0.8) |
| Brain | 9 (0.3) |
| Bone | 7 (0.2) |
| Other | 21 (0.7) |
| Missing | 31 (1.0) |
| Cancer histological subtype | |
| Adenocarcinoma | 2362 (77.9) |
| Squamous cell carcinoma | 305 (10.1) |
| Sarcoma | 32 (1.1) |
| Other | 333 (11.0) |
| Metastasis | 1310 (43.2) |
| Mediastinal, thoracic, or cervical lymph adenopathies | 792 (26.1) |
| Treatments initiated at inclusion* | |
| Surgical tumor resection | 1350 (44.5) |
| Chemotherapy (conventional or targeted) | 2921 (97.1) |
| Growth factors | 910 (30.1) |
| Radiotherapy | 239 (7.9) |
| Antiangiogenic agents | 231 (7.6) |
| Hormone therapy | 43 (1.4) |
| Parenteral nutrition | 89 (3.0) |
| . | N = 3032, no. (%) . |
|---|---|
| Site of the primary cancer | |
| Breast | 1023 (33.7) |
| Lung | 560 (18.5) |
| Colorectal | 472 (15.6) |
| Upper aerodigestive tract | 168 (5.5) |
| Pancreas | 162 (5.3) |
| Prostate | 108 (3.6) |
| Gastric | 103 (3.4) |
| Ovarian or peritoneal | 98 (3.2) |
| Bladder or urinary tract | 92 (3.0) |
| Liver or biliary tract | 65 (2.1) |
| Uterus | 64 (2.1) |
| Testis | 25 (0.8) |
| Kidney | 24 (0.8) |
| Brain | 9 (0.3) |
| Bone | 7 (0.2) |
| Other | 21 (0.7) |
| Missing | 31 (1.0) |
| Cancer histological subtype | |
| Adenocarcinoma | 2362 (77.9) |
| Squamous cell carcinoma | 305 (10.1) |
| Sarcoma | 32 (1.1) |
| Other | 333 (11.0) |
| Metastasis | 1310 (43.2) |
| Mediastinal, thoracic, or cervical lymph adenopathies | 792 (26.1) |
| Treatments initiated at inclusion* | |
| Surgical tumor resection | 1350 (44.5) |
| Chemotherapy (conventional or targeted) | 2921 (97.1) |
| Growth factors | 910 (30.1) |
| Radiotherapy | 239 (7.9) |
| Antiangiogenic agents | 231 (7.6) |
| Hormone therapy | 43 (1.4) |
| Parenteral nutrition | 89 (3.0) |
Missing data were distributed as follows: surgical tumor resection (n = 1), chemotherapy (n = 23), growth factors (n = 6), radiotherapy (n = 12), antiangiogenic agents (n = 5), hormone therapy (n = 7), parenteral nutrition (n = 36); details regarding treatments within each category are provided in supplemental Table 4.